Narrow search
Showing 1 - 10 of 876
Cover Image
Treatment of Locally Advanced Pancreatic Carcinoma in Sweden: A Health Economic Comparison of Palliative Treatment With Best Supportive Care Versus Palliative Treatment With Gemcit...
Tennvall, Gunnel Ragnarsont; Wilking, Nils - In: PharmacoEconomics 15 (1999) 4, pp. 377-384
Objective. Patients with pancreatic cancer have only short survival after diagnosis, irrespective of treatment. The aim of this study was to perform a health economic evaluation of present standard treatment (in most cases, palliative treatment in combination with best supportive care) versus...
Persistent link: https://www.econbiz.de/10005590429
Cover Image
Decreased Medical Expenditures for Care of HIV-Seropositive Patients: The Impact of Highly Active Antiretroviral Therapy at a US Veterans Affairs Medical Center
Mole, Larry; Ockrim, Kimberly; Holodniy, Mark - In: PharmacoEconomics 16 (1999) 3, pp. 307-315
Objective: To identify any changes in expenditures and in morbidity and mortality with the progression of treatment of …, laboratory and prescription costs, and morbidity and mortality rates. Main outcome measures and results: The 3 periods had … immunosuppression (defined as CD4+ lymphocyte counts <500 cells/mm3). Morbidity and mortality were not changed by the addition of dual …
Persistent link: https://www.econbiz.de/10005590457
Cover Image
Pharmacoeconomic Considerations in Treating Patients With Acute Leukaemia
Jonsson, Viggo; Hansen, Mogen Mork; Ljungman, Per; … - In: PharmacoEconomics 15 (1999) 2, pp. 167-178
Whereas individual cost-effectiveness analyses of new agents for acute leukaemia should be performed in target populations, any meaningful pharmacoeconomic evaluation of treatment options for this condition should include the many types of costs and outcomes in unselected, representative groups...
Persistent link: https://www.econbiz.de/10005590509
Cover Image
Choice of NSAID and Management Strategy in Rheumatoid Arthritis and Osteoarthritis: The Impact on Costs and Outcomes in the UK
McCabe, Chris J.; Akehurst, Ron L.; Kirsch, Jeff; … - In: PharmacoEconomics 14 (1998) 2, pp. 191-199
justifiable in terms of the mortality and morbidity gains associated with the new lower-risk NSAIDs. …
Persistent link: https://www.econbiz.de/10005590543
Cover Image
Simvastatin After Orthotopic Heart Transplantation: Costs and Consequences
Krobot, Karl J.; Wenke, Klaus; Reichart, Bruno - In: PharmacoEconomics 15 (1999) 3, pp. 279-289
Objective: Recent data indicate that the combination of a low cholesterol diet and simvastatin following heart transplantation is associated with significant reduction of serum cholesterol levels, lower incidence of graft vessel disease (GVD) and significantly superior 4-year survival rates than...
Persistent link: https://www.econbiz.de/10005449010
Cover Image
Counting the Costs of Drug-Related Adverse Events
White, T. Jeffrey; Arakelian, Annet; Rho, Jay P. - In: PharmacoEconomics 15 (1999) 5, pp. 445-458
mortality is equally significant and has been conservatively estimated at $US30 billion dollars annually, and could exceed $US … mortality has become an increasingly important requirement for reducing healthcare expenditures. This article will review …
Persistent link: https://www.econbiz.de/10005449050
Cover Image
Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction: Economic Evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from th...
Schadlich, Peter K.; Huppertz, Eduard; Brecht, Josef Georg - In: PharmacoEconomics 14 (1998) 6, pp. 653-669
lowered rates of total mortality and rehospitalisation due to heart failure. Design and Setting: The cost …
Persistent link: https://www.econbiz.de/10005449120
Cover Image
Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK
Nuijten, Mark; Meester, Liebeth; Waibel, Franz; Wait, … - In: PharmacoEconomics 16 (1999) 4, pp. 379-397
Objective: To simulate the treatment of postmenopausal women with advanced breast cancer from second-line hormone therapy to death, and to generate estimates of the cost and effectiveness of letrozole and megestrol in order to determine the incremental cost effectiveness of letrozole, expressed...
Persistent link: https://www.econbiz.de/10005449176
Cover Image
Cost Analysis of Palliative Care for Terminally Ill Cancer Patients in the UK After Switching from Weak to Strong Opioids
Guest, Julian F.; Hart, Warren M.; Cookson, Ronald F. - In: PharmacoEconomics 14 (1998) 3, pp. 285-297
Objective: We constructed a UK-based decision model of palliative care for terminally ill cancer patients who were switched from a weak to a strong opioid so that the expected direct healthcare costs in the UK could be estimated from the time a patient commenced a strong opioid until death....
Persistent link: https://www.econbiz.de/10005449313
Cover Image
Ensuring Appropriate Care in Epilepsy: An Overview of Epidemiological and Cost of Illness Considerations
Heaney, Dominic C.; Sander, Josemir W.A.S. - In: Disease Management and Health Outcomes 4 (1998) 6, pp. 303-313
Epilepsy is an important health problem throughout the world. In order to best manage epilepsy within a population, its epidemiological profile should be established. Epidemiological studies have shown that epilepsy is a very common, chronic condition that particularly affects the young and...
Persistent link: https://www.econbiz.de/10005243022